首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1344篇
  免费   148篇
  国内免费   65篇
耳鼻咽喉   2篇
儿科学   85篇
妇产科学   1篇
基础医学   87篇
口腔科学   43篇
临床医学   75篇
内科学   175篇
皮肤病学   59篇
神经病学   32篇
特种医学   12篇
外科学   341篇
综合类   149篇
现状与发展   1篇
预防医学   6篇
眼科学   71篇
药学   336篇
中国医学   56篇
肿瘤学   26篇
  2024年   1篇
  2023年   9篇
  2022年   14篇
  2021年   21篇
  2020年   26篇
  2019年   31篇
  2018年   43篇
  2017年   42篇
  2016年   39篇
  2015年   51篇
  2014年   56篇
  2013年   131篇
  2012年   62篇
  2011年   54篇
  2010年   66篇
  2009年   72篇
  2008年   78篇
  2007年   78篇
  2006年   86篇
  2005年   82篇
  2004年   53篇
  2003年   58篇
  2002年   59篇
  2001年   48篇
  2000年   37篇
  1999年   44篇
  1998年   30篇
  1997年   33篇
  1996年   29篇
  1995年   29篇
  1994年   12篇
  1993年   13篇
  1992年   11篇
  1991年   14篇
  1990年   12篇
  1989年   11篇
  1988年   11篇
  1987年   2篇
  1986年   3篇
  1985年   6篇
排序方式: 共有1557条查询结果,搜索用时 191 毫秒
1.
 目的探讨环孢素A(cyclosporine A,CsA)是否逆转野百合碱(monocrotaline,MCT)诱导的右心室重构及其作用机制的初步探讨。方法雄性SD大鼠随机分正常对照组,MCT模型组,CsA低、高剂量组(0.33和1mg·kg-1)。MCT造模后14~21d给CsA(ig,bid)。造模22d右心导管术检测右室收缩压(RVSP);称右室自由壁(RV)及左心室加室间隔(LV+SEP)重,计算右心肥大指数(RVHI=RV/LV+SEP);光镜及电镜观察右室结构变化;免疫组化检查右室心肌细胞PCNA的表达。结果CsA逆转MCT所引起RVSP、RVHI的升高(P<0.05或P<0.01)、右室心肌细胞肥大、线粒体肿胀变性及PCNA抗原的过表达。高剂量CsA作用更明显。结论CsA(1mg·kg-1 ig,bid)能明显逆转MCT诱导的右室重构,其机制可能与降低右室后负荷及抑制右室心肌细胞肥大有关。  相似文献   
2.
目的通过监测肾移植后病人环孢素A(CsA)全血浓度 ,提出CsA在三联免疫抑制用药方案中的理想治疗窗。方法用特异性荧光偏振免疫法测定CsA全血浓度 ,对521例病人监测3275次 ,按术后时间及临床表现分组比较。结果肾移植后<1 ,、1~3、3~6、6~12个月、1~2和>2年的CsA全血谷浓度的理想治疗窗应分别为250~450、200~400、150~300、100~250、100~200和100~180μg/L。结论CsA全血浓度在上述范围内 ,中毒反应和排异反应明显减少  相似文献   
3.
Histamine-type 2 antagonists (H2-blockers) as represented by cimentidine have been shown to adversely affect renal allograft function, particularly when coadministered with cyclosporine, currently a major immunosuppressant. To determine whether or not a newer and more powerful H2-blocker, famotidine, would produce similar adverse effects, we assessed seven cyclosporine-treated renal allograft recipients with regard to changes in their renal function on or off the H2-blocker over a one-week period. Neither the administration nor withdrawal of famotidine (20–40 mg/day) resulted in any significant changes in serum creatine, BUN, urine output or cyclosporine trough levels, suggesting that famotidine can be safely administered as an H2-blocker to cyclosporine-treated renal allograft recipients.  相似文献   
4.
The natural history of uveitis   总被引:8,自引:0,他引:8  
Summary Inflammatory diseases of the eye were known to the ancients, but only recently have the underlying mechanisms to this problem become better defined. During the middle portion of this century, most cases of uveitis thought to be caused by infectious agents, such as those responsible for syphilis and tuberculosis. Since then, it has become clear that endogenous mechanisms of immunomodulation play an important role in these disorders, which along with environmental and genetic factors make up an important triad. Animals studies have indicated the pivotal role of the T-cell in many of these disorders. The development of T-cell lines has helped to further delineate cell to cell interactions that occur during an ocular inflammatory event. The presence in the eye of uveitogenic antigens raises the strong possibility of autoimmune driven processes as well, similar to what is seen in the animal models. The better understanding of ocular inflammatory mechanisms has led to improved therapeutic strategies, including Sandimmune, and more recently Cyclosporine G, a related compound that may be less nephrotoxic. Newer therapeutic strategies will focus on even more novel modes of immunomodulation, probably without the use of medications.  相似文献   
5.
Few studies used paired kidneys for comparison between tacrolimus and cyclosporine in renal transplantation. Most of the published data used whole blood trough levels for drug monitoring. However, the use of limited sampling strategy and abbreviated formula to estimate the 12-h area under concentration-time curve (AUC(0-12)) allowed better prediction of drug exposure. Sixty-six first cadaveric renal transplant recipients receiving paired kidneys were randomized to receive either tacrolimus-based (n = 33) or cyclosporine microemulsion (Neoral)-based therapies (n = 33). Abbreviated AUC(0-12) was used for drug monitoring and dose titration. Mean follow-up duration was 2.8 +/- 2 years. The patient and graft survival were comparable. Fewer incidence of acute rejection was observed in tacrolimus group (15% vs. 27.3%) though the difference was not significant (P = 0.23). The absolute value and the rate of decline of creatinine clearance were both significantly better in tacrolimus-treated patients. Prevalence of hypertension, post-transplant diabetes mellitus, infection, and malignancy were similar in both groups. Prevalence of hypercholesterolemia (11/33 vs. 4/33) and gum hypertrophy (6/33 vs. 1/33) was more common in cyclosporine-treated patients (P = 0.04 in both parameters). This was the first prospective, randomized study with paired kidney analysis showing the renal function was significantly better in tacrolimus-treated patients than in cyclosporine-treated patients.  相似文献   
6.
罗格列酮对实验性慢性环孢素肾病的作用   总被引:5,自引:0,他引:5  
目的 探讨罗格列酮(RSG)对慢性环孢素肾病(CCN)大鼠模型的肾保护作用。 方法 低盐饮食基础上建立CCN大鼠模型,其中1组模型鼠用RSG同时灌胃。分别在实验开始后第14天和第35天处死动物,检测血浆和肾组织血管紧张素Ⅱ(AngⅡ)、AngⅡ1型受体(AT1R)、转化生长因子β1(TGF-β1)、细胞外调节蛋白激酶(p-ERK)、α-SMA和纤连蛋白(FN)的表达。在体外用不同浓度的CsA和RSG孵育NRK细胞。RT-PCR检测肾皮质TGF-β1,Western印迹分析检测FN、AT1R、p-ERK水平。 结果 RSG可改善环孢素A导致的大鼠肌酐清除率的下降[(0.586±0.094)比(1.072±0.105)ml&#8226;min-1&#8226;kg-1,P < 0.01]、血浆和肾组织AngⅡ水平增加(P < 0.01)、肾间质单核细胞浸润(P < 0.01)、肾间质纤维化(1.707±0.019 比 2.335±0.022,P < 0.01)、肾组织α-SMA表达增加(P < 0.01)、肾皮质TGF-β1 mRNA水平增加(P < 0.01)、NRK细胞FN、AT1R和p-ERK蛋白水平增加(P < 0.05)。 结论 RSG可能通过减轻炎细胞浸润、影响AngⅡ作用和下调TGF-β1等途径减轻CsA所致的肾组织损伤。  相似文献   
7.
Large granular lymphocytic (LGL) leukaemia and chronic natural killer cell lymphocytosis (CNKL) are chronic indolent disorders often associated with neutropenia and constitutional symptoms. Severe anaemia occurs in about 20% of patients and is currently treated with corticosteroids followed by oral cyclophosphamide in non-responders. 30% of patients fail initial measures, and salvage therapy is inadequate. We describe three transfusion-dependent patients (two with T-LGL leukaemia, one with CNKL) refractory to corticosteroids, cyclophosphamide, and in one case fludarabine. Cyclosporine A (CSA) initiation resulted in prompt transfusion-independence and was well tolerated in all patients, making it an attractive alternative therapy for this disorder.  相似文献   
8.
The influence of experimentally induced hepatic dysfunction on the pharmacokinetics of Cyclosporine A (CsA) was determined in dogs. The pharmacokinetics of oral (PO) and intravenous (IV) CsA were studied before and after 70 per cent hepatectomy or complete bile duct ligation (CBDL). Changes in liver function were monitored by serial measurements of serum bilirubin, and by the maximum removal rate (Rmax) and plasma disappearance rate (ICG-K) of indocyanine green (ICG). Concentrations of CsA in whole blood were measured by HPLC. Seventy per cent hepatectomy caused significant liver dysfunction: the ICG-Rmax decreased by 47.7±7.1 per cent (mean±SD) and the ICG-K decreased by 61.3±9.7 per cent during the first week after hepatectomy. At the same time, the systemic clearance (CLs) of IV-CsA decreased by 43.9±8.2 per cent, the area under the concentration curve (AUC) of IV-CsA increased by 35.4±20.8 per cent and the bioavailability of CsA decreased by 26.4±14.8 per cent. CBDL also induced significant liver dysfunction: the ICG-Rmax decreased by 39.1±12.8 per cent and the ICG-K decreased by 65.6±3.6 per cent in the second week after the operation. During the same period, the AUC of PO-CsA decreased by 69.9±10.7 per cent and the bioavailability of CsA also decreased markedly by 73.9±15.6 per cent. These data indicate that hepatic impairment significantly influences the pharmacokinetics of CsA, not only by the changes in intestinal absorption, but also by those in hepatic, metabolism. Dose adjustment is therefore necessary in the presence of hepatic dysfunction in order to maintain an adequate blood concentration of CsA without causing side effects. This research was performed in the Department of Surgery, University of Pittsburgh Health Center, University of Pittsburgh, USA  相似文献   
9.
Chronic rejection accounted for 32% of all graft losses in 7123 pediatric transplants. In a previous study acute, multiple acute and late acute rejections were risk factors for the development of chronic rejection. We postulated that the recent decrease in acute rejections would translate into a lower risk for chronic rejection among patients with recent transplants. We reviewed our data on patients transplanted from 1995 to 2000, and using multivariate analysis and a proportional hazards model developed risk factors for patients whose grafts had failed due to chronic rejection. A late initial rejection increased the risk of chronic rejection graft failure 3.6-fold (p < 0.001), while a second rejection resulted in further increase of 4.2-fold (p < 0.001). Recipients who received less than 5 mg/kg of cyclosporine at 30 days post-transplant had a relative risk (RR) of 1.9 (p = 0.02). Patients transplanted from 1995 to 2000 had a significantly lower risk (RR = 0.54, p < 0.001) of graft failure from chronic rejection than those who received their transplants earlier (1987-94). Since we were able to demonstrate that there is a decreased risk of chronic rejection graft failure in our study cohort, we would conclude that the goal of future transplants should be to minimize acute rejections.  相似文献   
10.
BACKGROUND: The deliberate use of ketoconazole to reduce the need for cyclosporine (CsA) is not new, but it is particularly relevant because of the high cost of CsA. Many studies have documented this benefit in renal and cardiac transplants, but this co-administration has not been reported in patients with nephrotic syndrome. METHODS: This retrospective study included 207 nephrotic patients who were steroid resistant, dependent or frequent relapsers and received CsA therapy. Among these patients 153 received daily ketoconazole therapy in a dose of 50 mg with concomitant decrease of one-third of the CsA dose while 54 patients received CsA alone. The majority of our cases were children (179 were below 18 years) and male to female ratio was 1.7:1. RESULTS: The great majority of the study population received the drugs for 1-2 years. Patients who received CsA and ketoconazole were comparable with those who received CsA alone regarding age, sex, duration of renal disease, renal pathology, severity of nephrotic syndrome, renal function, hepatic function and steroid response. Co-administration of ketoconazole significantly reduced mean doses of CsA by 37% after 1 month and 47% at 1 year with overall net cost savings of 37%. Hepatic functions remained within the normal range in both groups. Additionally, co-administration of ketoconazole significantly improved the response to CsA therapy, successful steroid withdrawal and decreased the frequency of renal impairment. CONCLUSIONS: Co-administration of keto with CsA in idiopathic nephrotic patients significantly reduces CsA costs and may improve its response.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号